<DOC>
	<DOCNO>NCT00002892</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . It yet know whether interferon alfa follow surgery effective surgery alone treat patient melanoma . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa therapy follow surgery treat patient stage II , stage III , recurrent melanoma .</brief_summary>
	<brief_title>Interferon Alfa No Further Therapy Following Surgery Treating Patients With Stage II , Stage III , Recurrent Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect adjuvant low-dose extended-duration interferon alfa disease-free overall survival patient completely resect malignant melanoma high risk recurrence . II . Determine correlation patient age sex effect interferon therapy disease-free overall survival . III . Describe toxic effect treatment . IV . Evaluate economic implication implement effective interferon therapy patient . OUTLINE : This randomize study . Patients stratified age , sex , disease status entry , participate institution . Patients randomized observation receive interferon alfa subcutaneous injection 3 time weekly 2 year , disease progression toxicity intervenes . Patients follow monthly 6 month , quarterly 18 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 1,000 patient enter 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma definitively resect within 12 week prior entry One follow category : Stage II disease ( great 4 mm Breslow thickness ) Stage III disease ( regional lymph node involvement ) Recurrent nonnodal superficial regional disease ( local transit ) Recurrent regional nodal involvement PATIENT CHARACTERISTICS : Able tolerate interferon No second malignancy except curatively treat : Carcinoma cervix Nonmelanomatous skin cancer No pregnant nursing woman PRIOR CONCURRENT THERAPY : No prior immunosuppressive therapy , include systemic steroid No prior biologic therapy Recovered surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>